A large multicountry observational study has provided a detailed contemporary description of the clinical characteristics and outcomes for patients with hereditary transthyretin amyloidosis. The research, known as the OverTTuRe study, analyzed data from five countries to understand the real-world trajectory of this progressive disease. The findings highlight significant heterogeneity in clinical manifestations and outcomes across different patient phenotypes and national healthcare systems. The study was published in Cardiology and Therapy and represents a significant effort to characterize the disease journey using secondary healthcare data.
Hereditary transthyretin amyloidosis, or ATTRv, is a clinically heterogeneous and potentially fatal condition caused by the accumulation of misfolded transthyretin proteins in various organ systems. The disease predominantly affects the heart and peripheral nerves, leading to cardiomyopathy and polyneuropathy. Because early symptoms are often non-specific and can mimic other common conditions, patients frequently experience substantial diagnostic delays. These delays can lead to misdiagnosis and inappropriate treatments, which are associated with worse clinical outcomes for individuals living with the disease.
The OverTTuRe study was a retrospective, observational, and longitudinal analysis that utilized secondary data from electronic health records, insurance claims databases, and healthcare registries. The research team identified patients diagnosed with ATTRv amyloidosis in the United States, the United Kingdom, Japan, Denmark, and Sweden. The study period varied by country, with data collection spanning from 2014 to 2023 in most regions. This multicountry approach allowed researchers to assess the epidemiology of the disease across diverse healthcare settings and patient populations in North America, Europe, and East Asia.
In total, the study identified 1,502 patients with hereditary ATTR amyloidosis. The cohort was segmented into two primary phenotypic groups: those with polyneuropathy, referred to as ATTRv-PN, and those with a mixed phenotype involving both cardiac and neurological manifestations. The ATTRv-PN phenotype was predominant across all countries, accounting for 51.3% to 63.7% of the identified patients. However, a considerable proportion of patients, ranging from 36.3% to 48.8%, presented with the mixed phenotype. Patients with the polyneuropathy phenotype were generally younger and had a higher proportion of female participants compared to those with the mixed phenotype.
One of the most significant findings of the study was the extent of diagnostic delays experienced by patients. The median time from the initial recording of any noncardiac manifestation to a formal diagnosis varied significantly by country. In the United States, these delays were the longest, with a median of 2.9 years for patients with the polyneuropathy phenotype and 2.4 years for those with the mixed phenotype. In contrast, delays in Japan were much shorter, ranging from 0 to 0.7 years. These variations suggest that factors beyond clinical presentation, such as healthcare system structures and coding practices, may influence the time to diagnosis.
Cardiac manifestations were particularly frequent in patients with the mixed phenotype. Heart failure was the most common initial cardiac symptom, affecting between 40.4% and 68.2% of patients depending on the country. The median time from the first cardiac manifestation to diagnosis was shorter than for noncardiac symptoms, ranging from 0.4 to 1.6 years. However, specific conditions like aortic valve stenosis in Sweden were associated with longer delays, reaching a median of 3.5 years.
Healthcare resource utilization was high for both phenotypes in the years preceding diagnosis. Outpatient visits were the most frequent type of healthcare encounter, indicating that patients were interacting with the healthcare system repeatedly before receiving an accurate diagnosis. All-cause hospitalizations were also common, with 38.6% to 88.9% of patients experiencing at least one hospitalization in the five years before diagnosis. The median length of stay for these hospitalizations varied by country and phenotype, ranging from 3.0 to 7.0 days. This high burden of utilization underscores the complexity of managing patients with non-specific symptoms in a real-world setting.
Following diagnosis, access to treatment remained a significant challenge for many patients. In most countries, the majority of patients did not receive any specific ATTR amyloidosis treatment during the study period. In the United States, 97.2% of patients with the polyneuropathy phenotype did not receive treatment. This lack of treatment access may be attributed to the late approval of certain therapies, such as TTR gene silencers, and varying reimbursement policies across different national healthcare systems. Sweden was an exception, where a higher proportion of patients received treatment, primarily consisting of TTR protein stabilizers.
Mortality and hospitalization risks in the five years following diagnosis varied considerably across countries and phenotypes. Five-year all-cause mortality for patients with the polyneuropathy phenotype ranged from 14.6% in Sweden to 36.2% in the United Kingdom. For patients with the mixed phenotype, mortality rates were higher, ranging from 21.0% in Japan to 73.0% in the United Kingdom. The probability of a first all-cause hospitalization also increased over time, with rates at five years post-diagnosis ranging from 23.5% to 66.2% for the polyneuropathy phenotype. These outcomes highlight the serious nature of the disease and the impact of delayed diagnosis and treatment on patient survival.
The study acknowledges several limitations, primarily related to the use of secondary data sources that are not originally designed for research purposes. Differences in data collection methods and coding practices across countries may have influenced the observed findings, making direct between-country comparisons difficult. Additionally, the study lacked a control population and did not include patient-reported outcomes or genetic variant data. Despite these limitations, the use of large, nationally representative data sources supports the generalizability of the findings in a real-world context.
The results of the OverTTuRe study emphasize the need for heightened clinical suspicion among healthcare providers to facilitate earlier diagnosis. The heterogeneous and systemic nature of ATTR amyloidosis makes it a diagnostic challenge, particularly when symptoms mimic other common conditions. Early recognition of the constellation of possible symptoms is crucial for identifying at-risk patients. The study suggests that improved awareness and better diagnostic practices could help reduce the significant delays currently experienced by patients.
Timely access to targeted therapies is also essential for improving patient outcomes. The emergence of novel disease-modifying therapies, including TTR protein stabilizers and gene silencers, offers new hope for managing the disease. However, the study shows that access to these treatments is not uniform across all regions. Expanding the availability of these therapies and streamlining referral networks could help ensure that patients receive appropriate care earlier in the disease course. A multidisciplinary approach to care, encompassing early diagnosis and guideline-directed treatment, is recommended to improve the quality of life for individuals with hereditary ATTR amyloidosis.
Subject of Research: Clinical characteristics and outcomes of hereditary ATTR amyloidosis in a multicountry observational study
Article Title: Contemporary Description of Clinical Characteristics and Outcomes in Patients with Hereditary ATTR Amyloidosis: Results from the Multicountry OverTTuRe Study
Article References: Alexander, K. M., Kohsaka, S., Poulsen, S. H., Terkelsen, A. J., Smith, J. G., Sundström, J., Wright, J., Järbrink, K., Bhimjiyani, A. G., Davis, L., Matsue, Y., Anderson, L. J., & Pilebro, B. (2026). Contemporary Description of Clinical Characteristics and Outcomes in Patients with Hereditary ATTR Amyloidosis: Results from the Multicountry OverTTuRe Study. Cardiology and Therapy, 15(2), 201-229. https://doi.org/10.1007/s40119-026-00450-y
Image Credits: AI Generated
DOI: 10.1007/s40119-026-00450-y
Keywords: ATTR amyloidosis, hereditary disease, diagnostic delay, multicountry study, cardiology, neurology, healthcare utilization, observational research, Contemporary, Description, Clinical, Characteristics
News Source: Ophelia Keating. (November 9, 2026). Multicountry Study Maps Diagnostic Delays in Hereditary ATTR Amyloidosis. Scienmag.



